Biologics in Systemic Sclerosis

Author(s): Jingxiu Xuan, Long Shen, Chongjie Zhang, Julian L. Ambrus Jr.

Journal Name: Current Pharmaceutical Biotechnology

Volume 15 , Issue 6 , 2014

Become EABM
Become Reviewer
Call for Editor


Systemic sclerosis (scleroderma) is a heterogeneous autoimmune disorder characterized by collagen overproduction that leads to cutaneous and internal organs sclerosis and pulmonary arterial hypertension. SSc has high morbidity and mortality. SSc pathogenesis is uncertain. At present most therapies of SSc are symptomatic. Effective therapeutic approaches are lacking. Accompanying a growing understanding of SSc pathogenesis, various key mediators are being evaluated as the therapeutic targets. This review described the effects of these key mediators in SSc.

Keywords: Antibodies, biologics, fibrosis, pathogenesis, systemic sclerosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 10 September, 2014
Page: [549 - 557]
Pages: 9
DOI: 10.2174/138920101506140910150749
Price: $65

Article Metrics

PDF: 39